JP2016501865A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016501865A5 JP2016501865A5 JP2015544133A JP2015544133A JP2016501865A5 JP 2016501865 A5 JP2016501865 A5 JP 2016501865A5 JP 2015544133 A JP2015544133 A JP 2015544133A JP 2015544133 A JP2015544133 A JP 2015544133A JP 2016501865 A5 JP2016501865 A5 JP 2016501865A5
- Authority
- JP
- Japan
- Prior art keywords
- therapy
- composition
- tlves
- tms
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002560 therapeutic procedure Methods 0.000 claims 24
- 239000000203 mixture Substances 0.000 claims 23
- 230000003042 antagnostic Effects 0.000 claims 9
- 239000005557 antagonist Substances 0.000 claims 9
- 230000000638 stimulation Effects 0.000 claims 6
- YQEZLKZALYSWHR-UHFFFAOYSA-N Calypsol Chemical group C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 claims 5
- 229960003299 ketamine Drugs 0.000 claims 5
- 210000003625 Skull Anatomy 0.000 claims 3
- 230000033764 rhythmic process Effects 0.000 claims 3
- 230000002159 abnormal effect Effects 0.000 claims 2
- 230000003444 anaesthetic Effects 0.000 claims 2
- 201000009541 complex regional pain syndrome Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000003461 thalamocortical Effects 0.000 claims 2
- 206010004939 Bipolar I disease Diseases 0.000 claims 1
- 206010004938 Bipolar disease Diseases 0.000 claims 1
- 206010013654 Drug abuse Diseases 0.000 claims 1
- 102000018899 Glutamate Receptors Human genes 0.000 claims 1
- 108010027915 Glutamate Receptors Proteins 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N NMDA Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 claims 1
- 210000003928 Nasal Cavity Anatomy 0.000 claims 1
- 208000009205 Tinnitus Diseases 0.000 claims 1
- 230000001054 cortical Effects 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 201000001947 reflex sympathetic dystrophy Diseases 0.000 claims 1
- 230000000542 thalamic Effects 0.000 claims 1
- 231100000886 tinnitus Toxicity 0.000 claims 1
Claims (22)
- 経頭蓋低電圧電気刺激（ｔｒａｎｓｃｒａｎｉａｌ ｌｏｗ ｖｏｌｔａｇｅ ｅｌｅｃｔｒｉｃａｌ ｓｔｉｍｕｌａｔｉｏｎ（ＴＬＶＥＳ））療法又は経頭蓋磁気刺激（ｔｒａｎｓｃｒａｎｉａｌ ｍａｇｎｅｔｉｃ ｓｔｉｍｕｌａｔｉｏｎ（ＴＭＳ））療法を受けている患者の視床皮質律動異常に関連する症状を処置するための解離性麻酔薬を含む医薬組成物であって、前記ＴＬＶＥＳ療法又は前記ＴＭＳ療法は、頭蓋への外用のためのものであり、前記組成物は、静脈内投与、筋肉内投与、経口投与、鼻腔内投与又は吸入投与のためのものである、組成物。
- 前記解離性麻酔薬は、ＮＭＤＡ型グルタミン酸受容体（ＮＭＤＡＲ）アンタゴニストである請求項１に記載の組成物。
- 前記ＮＭＤＡＲアンタゴニストは、ケタミンである請求項２に記載の組成物。
- 前記ＴＬＶＥＳ療法又は前記ＴＭＳ療法は、前記ＮＭＤＡＲアンタゴニストの投与前、投与時及び投与後に適用される請求項１に記載の組成物。
- プライミング処置を更に備える請求項１に記載の組成物。
- 前記ＴＬＶＥＳ療法又は前記ＴＭＳ療法は、３から７日の間隔で繰り返される請求項１に記載の組成物。
- 前記視床皮質律動異常に関連する症状は、耳鳴りである請求項１に記載の組成物。
- 前記視床皮質律動異常に関連する症状は、薬物乱用である請求項１に記載の組成物。
- 経頭蓋低電圧電気刺激（ｔｒａｎｓｃｒａｎｉａｌ ｌｏｗ ｖｏｌｔａｇｅ ｅｌｅｃｔｒｉｃａｌ ｓｔｉｍｕｌａｔｉｏｎ（ＴＬＶＥＳ））療法又は経頭蓋磁気刺激（ｔｒａｎｓｃｒａｎｉａｌ ｍａｇｎｅｔｉｃ ｓｔｉｍｕｌａｔｉｏｎ（ＴＭＳ））療法を受けている患者の疼痛を処置するためのＮＭＤＡ型グルタミン酸受容体（ＮＭＤＡＲ）アンタゴニストを含む医薬組成物であって、前記ＴＬＶＥＳ療法又は前記ＴＭＳ療法は、頭蓋への外用のためのものであり、前記組成物は、静脈内投与、筋肉内投与、経口投与、鼻腔内投与又は吸入投与のためのものである、組成物。
- 前記ＴＬＶＥＳ療法又は前記ＴＭＳ療法は、前記ＮＭＤＡＲアンタゴニストの投与前、投与時及び投与後に適用される請求項９に記載の組成物。
- 前記ＮＭＤＡＲアンタゴニストは、約５０−５００ｍｇの用量又は約０．５ｍｇ／ｋｇから約５ｍｇ／ｋｇの用量でのケタミンである請求項９に記載の組成物。
- 前記ケタミンは、約３０から６０秒間注入される請求項１１に記載の組成物。
- プライミング処置を更に備える請求項９に記載の組成物。
- 前記ＴＬＶＥＳ療法又は前記ＴＭＳ療法は、３から７日の間隔で少なくとも５回繰り返される請求項９に記載の組成物。
- 前記疼痛は、複合性局所疼痛症候群又は反射性交感神経性ジストロフィーに関連する請求項９に記載の組成物。
- 経頭蓋低電圧電気刺激（ｔｒａｎｓｃｒａｎｉａｌ ｌｏｗ ｖｏｌｔａｇｅ ｅｌｅｃｔｒｉｃａｌ ｓｔｉｍｕｌａｔｉｏｎ（ＴＬＶＥＳ））療法又は経頭蓋磁気刺激（ｔｒａｎｓｃｒａｎｉａｌ ｍａｇｎｅｔｉｃ ｓｔｉｍｕｌａｔｉｏｎ（ＴＭＳ））療法を受けている患者のうつ病を処置するためのＮＭＤＡ型グルタミン酸受容体（ＮＭＤＡＲ）アンタゴニストを含む医薬組成物であって、前記ＴＬＶＥＳ療法又は前記ＴＭＳ療法は、頭蓋への外用のためのものである、組成物。
- 前記ＴＬＶＥＳ療法又は前記ＴＭＳ療法は、前記ＮＭＤＡＲアンタゴニストの投与前、投与時及び投与後に適用される請求項１６に記載の組成物。
- 前記ＮＭＤＡＲアンタゴニストは、約５０−５００ｍｇの用量又は約０．５ｍｇ／ｋｇから約５ｍｇ／ｋｇの用量のケタミンである請求項１６に記載の組成物。
- 前記ケタミンは、約３０から６０秒間注入される請求項１８に記載の組成物。
- プライミング処置を更に備える請求項１６に記載の組成物。
- 前記ＴＬＶＥＳ療法又は前記ＴＭＳ療法は、３から７日の間隔で少なくとも５回繰り返される請求項１６に記載の組成物。
- 前記うつ病は、双極性うつ病である請求項１６に記載の組成物。
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261729625P | 2012-11-25 | 2012-11-25 | |
| US61/729,625 | 2012-11-25 | ||
| US13/826,250 | 2013-03-14 | ||
| US13/826,250 US8974365B2 (en) | 2012-11-25 | 2013-03-14 | Treatment of thalamocortical dysrhythmia |
| PCT/US2013/071275 WO2014081948A1 (en) | 2012-11-25 | 2013-11-21 | Treatment of thalamocortical dysrhythmia |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018229815A Division JP2019065021A (ja) | 2012-11-25 | 2018-12-07 | 視床皮質律動異常の処置 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016501865A JP2016501865A (ja) | 2016-01-21 |
| JP2016501865A5 true JP2016501865A5 (ja) | 2017-01-12 |
Family
ID=50773848
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015544133A Pending JP2016501865A (ja) | 2012-11-25 | 2013-11-21 | 視床皮質律動異常の処置 |
| JP2018229815A Pending JP2019065021A (ja) | 2012-11-25 | 2018-12-07 | 視床皮質律動異常の処置 |
| JP2020117607A Pending JP2020180141A (ja) | 2012-11-25 | 2020-07-08 | 視床皮質律動異常の処置 |
| JP2022161851A Pending JP2022188221A (ja) | 2012-11-25 | 2022-10-06 | 視床皮質律動異常の処置 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018229815A Pending JP2019065021A (ja) | 2012-11-25 | 2018-12-07 | 視床皮質律動異常の処置 |
| JP2020117607A Pending JP2020180141A (ja) | 2012-11-25 | 2020-07-08 | 視床皮質律動異常の処置 |
| JP2022161851A Pending JP2022188221A (ja) | 2012-11-25 | 2022-10-06 | 視床皮質律動異常の処置 |
Country Status (11)
| Country | Link |
|---|---|
| US (5) | US8974365B2 (ja) |
| EP (2) | EP2922591B1 (ja) |
| JP (4) | JP2016501865A (ja) |
| KR (4) | KR20150091323A (ja) |
| CN (1) | CN104981265A (ja) |
| CA (1) | CA2896568A1 (ja) |
| ES (1) | ES2882619T3 (ja) |
| HK (1) | HK1215687A1 (ja) |
| IL (2) | IL238979B (ja) |
| MX (1) | MX2015006444A (ja) |
| WO (1) | WO2014081948A1 (ja) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10155114B2 (en) * | 2014-06-03 | 2018-12-18 | Dirk De Ridder | Systems and methods of treating a neurological disorder in a patient |
| US10118038B2 (en) * | 2015-03-24 | 2018-11-06 | Dirk De Ridder | Methods of neuromodulation |
| US10201708B2 (en) | 2014-10-29 | 2019-02-12 | Dirk De Ridder | Method of treating a neurological disorder using network stimulation |
| WO2017141257A1 (en) * | 2016-02-21 | 2017-08-24 | Tech Innosphere Engineering Ltd. | Noninvasive electric brain stimulation system |
| US10596378B2 (en) * | 2016-10-18 | 2020-03-24 | Joseph Rustick | Method for treatment of depression using synaptic pathway training |
| US10905897B2 (en) * | 2016-10-20 | 2021-02-02 | Neuro-Laser Foundation, Inc. | Synergistic treatment methodologies using light therapy |
| US9950189B1 (en) * | 2016-10-20 | 2018-04-24 | Neuro-Laser Foundation Inc. | Treatment methodologies using light therapy |
| WO2019060298A1 (en) | 2017-09-19 | 2019-03-28 | Neuroenhancement Lab, LLC | METHOD AND APPARATUS FOR NEURO-ACTIVATION |
| KR20230047509A (ko) * | 2017-11-22 | 2023-04-07 | 치에-신 린 | 우울증의 예방 또는 치료용 벤조익산 또는 이의 염 및 유도체 |
| US11717686B2 (en) | 2017-12-04 | 2023-08-08 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to facilitate learning and performance |
| KR102099200B1 (ko) * | 2017-12-18 | 2020-04-09 | 서울대학교산학협력단 | 뇌 자극 장치 |
| US11478603B2 (en) | 2017-12-31 | 2022-10-25 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to enhance emotional response |
| US11364361B2 (en) | 2018-04-20 | 2022-06-21 | Neuroenhancement Lab, LLC | System and method for inducing sleep by transplanting mental states |
| WO2020056418A1 (en) | 2018-09-14 | 2020-03-19 | Neuroenhancement Lab, LLC | System and method of improving sleep |
| CN109481845B (zh) * | 2018-12-28 | 2022-04-01 | 深圳先进技术研究院 | 一种作用于不同脑区的经颅磁刺激的方法和相关装置 |
| CN110064117B (zh) * | 2019-03-27 | 2021-06-01 | 佛山职业技术学院 | 一种基于呐喊声音的心理宣泄交互方法及装置 |
| CN113631776B (zh) | 2019-03-28 | 2023-02-17 | 住友建机株式会社 | 挖土机及施工系统 |
| US11786694B2 (en) | 2019-05-24 | 2023-10-17 | NeuroLight, Inc. | Device, method, and app for facilitating sleep |
| CN113041501A (zh) * | 2021-03-22 | 2021-06-29 | 东南大学 | 联合磁刺激系统靶向视觉皮层快速抗抑郁的方法 |
| WO2022235576A1 (en) * | 2021-05-03 | 2022-11-10 | Wang Michael Z | Methods and compositions for treating depression |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5084007A (en) * | 1989-08-11 | 1992-01-28 | Malin David H | Method for chemical promotion of the effects of low current transcranial electrostimulation |
| US6132361A (en) * | 1994-11-28 | 2000-10-17 | Neotonus, Inc. | Transcranial brain stimulation |
| US5763393A (en) | 1996-05-17 | 1998-06-09 | Neurotherapeutics L.P. | Neuroactive peptides |
| US6176242B1 (en) * | 1999-04-30 | 2001-01-23 | Medtronic Inc | Method of treating manic depression by brain infusion |
| US6591138B1 (en) * | 2000-08-31 | 2003-07-08 | Neuropace, Inc. | Low frequency neurostimulator for the treatment of neurological disorders |
| US20110307029A1 (en) * | 2008-08-06 | 2011-12-15 | Cerephex Corporation | Brain stimulation methods for treating central sensitivity |
| US7687080B2 (en) * | 2002-11-25 | 2010-03-30 | Taraxos Inc. | Treatment of neuropathy |
| US8052591B2 (en) * | 2006-05-05 | 2011-11-08 | The Board Of Trustees Of The Leland Stanford Junior University | Trajectory-based deep-brain stereotactic transcranial magnetic stimulation |
| AU2005286733B2 (en) | 2004-09-23 | 2009-11-05 | Alexander Michalow | Methods for regulating neurotransmitter systems by inducing counteradaptations |
| US7603174B2 (en) * | 2004-10-21 | 2009-10-13 | Advanced Neuromodulation Systems, Inc. | Stimulation of the amygdalohippocampal complex to treat neurological conditions |
| CN101686945A (zh) * | 2004-11-23 | 2010-03-31 | 埃德莫斯药品有限公司 | 包含持续释放的包衣或基质和nmda受体拮抗剂的组合物，以及向受治疗者施用该nmda受体拮抗剂的方法 |
| US7619007B2 (en) * | 2004-11-23 | 2009-11-17 | Adamas Pharmaceuticals, Inc. | Method and composition for administering an NMDA receptor antagonist to a subject |
| US8676330B2 (en) * | 2009-03-20 | 2014-03-18 | ElectroCore, LLC | Electrical and magnetic stimulators used to treat migraine/sinus headache and comorbid disorders |
| CN101432011A (zh) * | 2006-02-27 | 2009-05-13 | 亚历山大·米哈洛 | 通过诱导逆适应调节神经递质系统的方法 |
| US20100113959A1 (en) * | 2006-03-07 | 2010-05-06 | Beth Israel Deaconess Medical Center, Inc. | Transcranial magnetic stimulation (tms) methods and apparatus |
| KR20090029690A (ko) * | 2006-03-22 | 2009-03-23 | 마운트 시나이 스쿨 오브 메디신 오브 뉴욕 유니버시티 | 우울증을 치료하기 위한 케타민의 투여 방법 |
| US7949403B2 (en) * | 2007-02-27 | 2011-05-24 | Accelerated Care Plus Corp. | Electrical stimulation device and method for the treatment of neurological disorders |
| CA2722776A1 (en) * | 2008-05-09 | 2009-11-12 | Emory University | Nmda receptor antagonists for the treatment of neuropsychiatric disorders |
| EP2310094B1 (en) * | 2008-07-14 | 2014-10-22 | Arizona Board Regents For And On Behalf Of Arizona State University | Devices for modulating cellular activity using ultrasound |
| EP2321007B1 (en) * | 2008-08-04 | 2016-10-12 | The Trustees of Columbia University in the City of New York | Apparatus and systems for magnetic stimulation |
| WO2010071846A2 (en) | 2008-12-19 | 2010-06-24 | Afraxis, Inc. | Compounds for treating neuropsychiatric conditions |
| CN102413873B (zh) * | 2009-03-02 | 2014-07-16 | 耶德研究和发展有限公司 | 用于经颅磁刺激的磁结构和定时方案 |
| US8951968B2 (en) | 2009-10-05 | 2015-02-10 | Northwestern University | Methods of treating depression and other related diseases |
| WO2011044535A2 (en) * | 2009-10-09 | 2011-04-14 | Afraxis, Inc. | 8-ethyl-6-(aryl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders |
| SG181733A1 (en) * | 2009-12-15 | 2012-07-30 | Neurop Inc | Compounds for the treatment of neurologic disorders |
| US20130096363A1 (en) * | 2010-04-02 | 2013-04-18 | M. Bret Schneider | Neuromodulation of deep-brain targets by transcranial magnetic stimulation enhanced by transcranial direct current stimulation |
| US20140058189A1 (en) * | 2012-02-20 | 2014-02-27 | William F. Stubbeman | Systems and methods using brain stimulation for treating disorders |
-
2013
- 2013-03-14 US US13/826,250 patent/US8974365B2/en active Active
- 2013-11-21 KR KR1020157015152A patent/KR20150091323A/ko not_active Application Discontinuation
- 2013-11-21 WO PCT/US2013/071275 patent/WO2014081948A1/en active Application Filing
- 2013-11-21 EP EP13856126.1A patent/EP2922591B1/en active Active
- 2013-11-21 KR KR1020237031477A patent/KR20230141875A/ko not_active Application Discontinuation
- 2013-11-21 ES ES13856126T patent/ES2882619T3/es active Active
- 2013-11-21 CN CN201380069664.7A patent/CN104981265A/zh active Pending
- 2013-11-21 JP JP2015544133A patent/JP2016501865A/ja active Pending
- 2013-11-21 MX MX2015006444A patent/MX2015006444A/es unknown
- 2013-11-21 CA CA2896568A patent/CA2896568A1/en active Pending
- 2013-11-21 EP EP21172714.4A patent/EP3915551A1/en active Pending
- 2013-11-21 KR KR1020207028289A patent/KR20200117062A/ko not_active IP Right Cessation
- 2013-11-21 KR KR1020227032393A patent/KR20220132667A/ko not_active Application Discontinuation
-
2015
- 2015-02-27 US US14/634,305 patent/US9649501B2/en active Active
- 2015-05-21 IL IL238979A patent/IL238979B/en active IP Right Grant
-
2016
- 2016-03-30 HK HK16103635.7A patent/HK1215687A1/zh unknown
-
2017
- 2017-04-19 US US15/491,612 patent/US10716950B2/en active Active
-
2018
- 2018-12-07 JP JP2018229815A patent/JP2019065021A/ja active Pending
-
2020
- 2020-04-12 IL IL273912A patent/IL273912A/en unknown
- 2020-07-08 JP JP2020117607A patent/JP2020180141A/ja active Pending
- 2020-07-20 US US16/933,397 patent/US20210101015A1/en not_active Abandoned
-
2022
- 2022-10-06 JP JP2022161851A patent/JP2022188221A/ja active Pending
-
2023
- 2023-09-05 US US18/461,499 patent/US20240207630A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016501865A5 (ja) | ||
| JP2020180141A5 (ja) | ||
| JP7398836B2 (ja) | Ｒ－ケタミンおよびその塩の医薬品としての応用 | |
| JP2020180141A (ja) | 視床皮質律動異常の処置 | |
| Kim et al. | Efficacy and safety of lidocaine infusion treatment for neuropathic pain: a randomized, double-blind, and placebo-controlled study | |
| JP2016518387A5 (ja) | ||
| JP2014528474A5 (ja) | ||
| JP2014515373A5 (ja) | ||
| JP2011173928A5 (ja) | ||
| JP2015515985A5 (ja) | ||
| RU2012108656A (ru) | Применение 4-аминопиридина для улучшения состояния при нейрокогнитивном и/или нейропсихиатрическом нарушении у пациентов с демиелинизирующими и другими заболеваниями нервной системы | |
| JP2009529502A5 (ja) | ||
| JP2013541583A5 (ja) | ||
| JP2013518124A5 (ja) | ||
| JP2017510607A5 (ja) | ||
| JP2015522015A5 (ja) | ||
| JP2015522077A5 (ja) | ||
| JP2016507500A5 (ja) | ||
| Guenther et al. | Selective 5-HT1A-R-agonist repinotan prevents remifentanil-induced ventilatory depression and prolongs antinociception | |
| JP2016505050A5 (ja) | ||
| JP2018529766A5 (ja) | ||
| JP2020500930A5 (ja) | ||
| Zhang et al. | Research advances in the clinical application of esketamine | |
| JP2013536206A5 (ja) | ||
| JP2015509934A5 (ja) |